ArticleJPGN reports2025
Impact of biologic induction dose and concomitant drugs on anti-drug antibody formation in a pediatric IBD cohort with high Hispanic representation.
Article in JPGN reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The use of biologic therapy is increasing in pediatric patients with inflammatory bowel disease (IBD). However, efficacy may be compromised by increased drug clearance and anti-drug antibodies (ADAs). Historically, concomitant immunomodulator therapy (CIT) has been used to prevent ADA formation. Pediatric studies evaluating CIT have focused largely on white, non-Hispanic patients and have demonstrated variable benefits. This study evaluated the utility of CIT in preventing ADAs in a pediatric IBD population with high Hispanic representation. Methods: We reviewed the charts of patients undergoing biologic induction at the Miller Children's Pediatric IBD Center between 2013 and 2023. Patients with missing therapeutic drug monitoring data or incomplete follow-up were excluded. Categorical variables were compared using chi-square or Fisher's exact tests, and continuous variables were analyzed using Results: Of 163 pediatric patients, 75 had Crohn's disease (CD) and 80 had ulcerative colitis (UC). High-dose infliximab (IFX) was protective against ADA formation ( Conclusions: High-dose IFX may obviate the need for CIT in ADA prevention in pediatric IBD. UC patients may benefit more from CIT than CD patients. Disparities in treatment timing and medication use among Hispanic UC patients highlight the need for further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.